Abstract
In Cameroon, recent studies have documented several cases of dengue infection in some urban areas, but dengue-malaria coinfection malaria was little investigated, especially in the East region. From the 6th July to the 4th September 2020, a case-control study including 50 cases (malaria-positive subjects) and 90 controls (non-malaria subjects) was carried out at the Bertoua Regional Hospital. Participants were prospectively enrolled and administered with a questionnaire to record information such as age, sex, dwelling place, dengue knowledge, and the environment’s quality. Blood specimens were then collected and screened for dengue infection using the NS1/IgG/IgM rapid diagnostic tests and hematological parameters were measured using a MINDRAY-type hemacytometer. Of the malaria patients, 14% (7/50) were tested positive for dengue fever against 66.66% for the controls (60/90). Most malaria patients had a secondary dengue infection (57.14%, 4/7) while most of the non-malaria patients faced a primary infection (61.66%, 37/60). In both groups, women were more exposed than men to dengue and there was a significant association between the dwelling place and dengue seropositivity. Moreover, young subjects <16 years old were significantly more associated with dengue than 16-30 years old (OR=16.24, P=0.042 for cases vs, OR=21, P=0.0001 for controls). The analysis of hematological parameters showed a significant decrease (P<0.001) in platelets in cases compared to control. These results suggest that dengue fewer targets malaria- than non- malaria patients with different serological characteristics in Bertoua city. However, co-infected patients demonstrated a greater clinical vulnerability than monoinfected patients, urging the need for epidemiological surveillance.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
The study was partly possible thanks to a research grant (F/6125-1) from International Foundation for Science, which helped us to acquire Dengue kits.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This study protocol was approved by the National Ethics Committee for Research on Human Health Ethical Clearance Number, 2020/01/58/ CE/CNERSH/SP. Permission for sample collection at BRH was granted by the Regional Delegate for Public Health of the East region (Authorization Number 622/L/MINSANTE/SG/DRSPE/BFP).
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
agdesy{at}yahoo.fr
nguelemeke{at}yahoo.fr
Data Availability
Data are available upon request to the corresponding author
